Regeneron Pharmaceuticals buys 23andMe assets for $256 million, aiming to maintain 23andMe's mission

From Yahoo Finance: 2025-05-19 11:45:00

Regeneron Pharmaceuticals acquires 23andMe’s assets for $256 million as part of 23andMe’s Chapter 11 bankruptcy protection. The deal is set to close in the third quarter of 2025 pending court approval.

Regeneron to purchase 23andMe’s personal genome service and health/research segments. The deal includes Regeneron’s commitment to comply with 23andMe’s privacy policies and laws regarding customer data protection.

Regeneron aims to maintain 23andMe’s mission of helping people understand their DNA and improve personal health while enhancing Regeneron’s health and wellness initiatives. Court-appointed privacy ombudsman will assess the impact on consumer privacy.

After reviewing Regeneron’s proposed purchase of 23andMe, a court-appointed consumer privacy ombudsman will report to the court on June 10. Regeneron plans to make 23andMe a subsidiary and uphold its personal genomics service.

23andMe’s Mark Jensen expresses satisfaction with the deal, ensuring customer privacy, choice, and consent regarding genetic data. The transaction maximizes the business’s value and allows 23andMe’s mission to continue.

Read more: Regeneron Pharmaceuticals to buy bankrupt 23andMe in $256M deal